0001171843-24-001275.txt : 20240311 0001171843-24-001275.hdr.sgml : 20240311 20240311101203 ACCESSION NUMBER: 0001171843-24-001275 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boylan James P CENTRAL INDEX KEY: 0001953094 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39696 FILM NUMBER: 24736883 MAIL ADDRESS: STREET 1: C/O ENAVATE SCIENCES STREET 2: 2884 SAND HILL RD., STE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Compass Therapeutics, Inc. CENTRAL INDEX KEY: 0001738021 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-500-8099 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Olivia Ventures, Inc. DATE OF NAME CHANGE: 20180419 4 1 ownership.xml X0508 4 2024-03-08 0 0001738021 Compass Therapeutics, Inc. CMPX 0001953094 Boylan James P C/O COMPASS THERAPEUTICS, INC. 80 GUEST STREET, SUITE 601 BOSTON MA 02135 1 0 0 0 0 Stock Option (Right to Buy) 1.96 2024-03-08 4 A 0 40000 0 A 2034-03-07 Common Stock 40000 40000 D The options vest over 48 substantially equal monthly installments starting April 8, 2024. The Reporting Person is a member of Enavate Sciences, LP ("Enavate"). Pursuant to an agreement with Enavate, the Reporting Person has agreed to receive and hold for the benefit of Enavate any securities issued under any stock options or other awards granted to him for his services as a director on the Issuer's board of directors. As such, the Reporting Person disclaims beneficial ownership of, and all right, title and interest in, the reported securities. /s/ Neil Lerner, as attorney-in-fact 2024-03-11